Formosa Pharmaceuticals and the Singapore Eye Research Institute (SERI) are launching a strategic research collaboration to develop next-generation ophthalmic formulations. Need for Ophthalmic Improvements The aim of the partnership is to address what the two parties say are “significant” unmet needs. In particular, they say, treatments for corneal and ocular surface diseases are lacking. The collaboration leverages Formosa’s proprietary APNT, or Active Pharmaceutical (ingredient) Nanop...